Accession PRJCA012927
Title Proteogenomics landscape of Acute Myeloid Leukemia
Relevance Medical
Data types Proteomics
Organisms Homo sapiens
Description Acute myeloid leukemia (AML) is a malignant hematological cancer with the worst prognosis of all leukemia categories. Here, we reported a comprehensive proteogenomic analysis of 101 Chinese AML patients, including proteomic, phosphoproteomic analysis and an ex vivo drug sensitivity analysis in addition to Whole exome and transcriptome sequencing. We explored the impact of genomic alterations on proteomic and phosphoproteomic characterizations, and also uncovered the protein and phosphosite panel as prognostic indicators. Proteome-based unsupervised clustering revealed three subtypes with different molecular characterizations and clinical outcomes. Further integrative analysis of drug sensitivity combined with proteomic data showed the novel therapeutic potential of cytarabine-disulfiram combo and PI3Ki-PDKi combo. Our data provided valuable resources for understanding the molecular alterations in AML pathogenesis and clinical therapeutic strategies.
Sample scope Multiisolate
Release date 2023-02-03
Publication
PubMed ID Article title Journal name DOI Year
37019911 Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia Nature Communications 10.1038/s41467-023-37381-4 2023
Grants
Agency program Grant ID Grant title
No funding support
Submitter Jia Li (jli@simm.ac.cn)
Organization Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Submission date 2022-11-01

Project Data

Resource name Description
BioSample (157)  show -